Trial · NCT04568434
Results by group48
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 48
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percent Change From Baseline in Fasting TG at Month 6 | Placebo | 11.52 | 95% Confidence Interval -5.321 to 28.356 | percent change | |
| Percent Change From Baseline in Fasting TG at Month 6 | Olezarsen 50 mg | -10.85 | 95% Confidence Interval -27.797 to 6.095 | percent change | |
| Percent Change From Baseline in Fasting TG at Month 6 | Olezarsen 80 mg | -31.99 | 95% Confidence Interval -49.031 to -14.940 | percent change | |
| Percent Change From Baseline in Fasting TG at Month 12 | Placebo | 20.89 | 95% Confidence Interval 1.016 to 40.764 | percent change | |
| Percent Change From Baseline in Fasting TG at Month 12 | Olezarsen 50 mg | -22.92 | 95% Confidence Interval -42.505 to -3.336 | percent change | |
| Percent Change From Baseline in Fasting TG at Month 12 | Olezarsen 80 mg | -38.50 | 95% Confidence Interval -58.187 to -18.815 | percent change | |
| Percent Change From Baseline in Fasting Apolipoprotein C-III (apoC-III) at Months 6 and 12 | Placebo | Month 6 | 7.57 | 95% Confidence Interval -5.229 to 20.359 | percent change |
| Percent Change From Baseline in Fasting Apolipoprotein C-III (apoC-III) at Months 6 and 12 | Olezarsen 50 mg | Month 6 | -57.91 | 95% Confidence Interval -71.193 to -44.631 | percent change |
| Percent Change From Baseline in Fasting Apolipoprotein C-III (apoC-III) at Months 6 and 12 | Olezarsen 80 mg | Month 6 | -66.13 | 95% Confidence Interval -79.437 to -52.823 | percent change |
| Percent Change From Baseline in Fasting Apolipoprotein C-III (apoC-III) at Months 6 and 12 | Placebo | Month 12 | 17.08 | 95% Confidence Interval 2.149 to 32.009 | percent change |
| Percent Change From Baseline in Fasting Apolipoprotein C-III (apoC-III) at Months 6 and 12 | Olezarsen 50 mg | Month 12 | -59.98 | 95% Confidence Interval -75.163 to -44.795 | percent change |
| Percent Change From Baseline in Fasting Apolipoprotein C-III (apoC-III) at Months 6 and 12 | Olezarsen 80 mg | Month 12 | -64.20 | 95% Confidence Interval -79.408 to -48.984 | percent change |
| Percentage of Participants With ≥ 40% Reduction in Fasting TG at Month 6 | Placebo | 4.3 | percentage of participants | ||
| Percentage of Participants With ≥ 40% Reduction in Fasting TG at Month 6 | Olezarsen 50 mg | 33.3 | percentage of participants | ||
| Percentage of Participants With ≥ 40% Reduction in Fasting TG at Month 6 | Olezarsen 80 mg | 40.9 | percentage of participants | ||
| Percent Change From Baseline in Fasting Apolipoprotein B-48 (apoB-48) at Months 6 and 12 | Placebo | Month 6 | 24.50 | 95% Confidence Interval -9.972 to 58.973 | percent change |
| Percent Change From Baseline in Fasting Apolipoprotein B-48 (apoB-48) at Months 6 and 12 | Olezarsen 50 mg | Month 6 | -8.78 | 95% Confidence Interval -42.976 to 25.406 | percent change |
| Percent Change From Baseline in Fasting Apolipoprotein B-48 (apoB-48) at Months 6 and 12 | Olezarsen 80 mg | Month 6 | -59.46 | 95% Confidence Interval -93.164 to -25.765 | percent change |
| Percent Change From Baseline in Fasting Apolipoprotein B-48 (apoB-48) at Months 6 and 12 | Placebo | Month 12 | -3.52 | 95% Confidence Interval -53.159 to 46.124 | percent change |
| Percent Change From Baseline in Fasting Apolipoprotein B-48 (apoB-48) at Months 6 and 12 | Olezarsen 50 mg | Month 12 | -36.41 | 95% Confidence Interval -77.689 to 4.860 | percent change |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04568434/results